Factors associated with anti-SARS-CoV-2 IgG antibody production in patients convalescing from COVID-19.
Anti-SARS-CoV-2 spike protein antibody
COVID-19
Convalescent
SARS-CoV-2
Journal
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
ISSN: 1437-7780
Titre abrégé: J Infect Chemother
Pays: Netherlands
ID NLM: 9608375
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
01
10
2020
revised:
01
12
2020
accepted:
12
01
2021
pubmed:
4
2
2021
medline:
14
5
2021
entrez:
3
2
2021
Statut:
ppublish
Résumé
Among patients with coronavirus disease 2019 (COVID-19), the factors that affect anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody production remain unclear. This study aimed to identify such factors among patients convalescing from COVID-19. This study comprised patients who had been diagnosed with COVID-19 between January 1 and June 30, 2020 and gave consent for anti-SARS-CoV-2 spike protein antibody measurement using enzyme-linked immunosorbent assay during their acute and/or convalescent phases. Factors related to elevated antibody titers and the relationship between the days from disease onset and the development of antibody titers were assessed. A total of 84 participants enrolled in the study. Nineteen participants had antibody titers measured during the convalescent phase only, and 65 participants had antibody titers measured during the acute and convalescent phases. The antibody titers peaked in weeks 5 and 6. The stepwise multivariate log-normal analysis revealed that male sex (P = 0.04), diabetes mellitus (P = 0.03), and high C-reactive protein levels during the disease course (P < 0.001) were associated with elevated IgG antibodies. Glucocorticoid use was not associated with antibody titers. The study found that high values of maximum CRP levels during the acute phase, male sex, and diabetes mellitus were associated with elevated antibody titers. Antibody titers tended to be highest in the first 5 or 6 weeks after the onset of symptoms.
Identifiants
pubmed: 33531292
pii: S1341-321X(21)00014-3
doi: 10.1016/j.jiac.2021.01.006
pmc: PMC7836855
pii:
doi:
Substances chimiques
Angiotensin Receptor Antagonists
0
Angiotensin-Converting Enzyme Inhibitors
0
Antibodies, Viral
0
Immunoglobulin G
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
808-813Informations de copyright
Copyright © 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no conflicts of interest.
Références
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
J Am Acad Dermatol. 2020 Aug;83(2):680-682
pubmed: 32446821
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
N Engl J Med. 2020 Sep 3;383(10):994
pubmed: 32649078
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
World J Pediatr. 2020 Jun;16(3):251-259
pubmed: 32193831
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496
pubmed: 32253318
JAMA. 2020 Aug 4;324(5):460-470
pubmed: 32492084
Nat Rev Rheumatol. 2011 May;7(5):282-9
pubmed: 21468143
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
J Med Virol. 2020 Oct;92(10):2050-2054
pubmed: 32383183
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034
pubmed: 32221519
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Cosmet Dermatol. 2020 Jul;19(7):1545-1547
pubmed: 32301221
Clin Infect Dis. 2020 Jul 28;71(15):769-777
pubmed: 32176772
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Drug Dev Res. 2020 Nov;81(7):771-776
pubmed: 32412125
Trends Immunol. 2020 May;41(5):355-359
pubmed: 32249063
JAMA. 2020 Apr 28;323(16):1582-1589
pubmed: 32219428
N Engl J Med. 2020 Oct 22;383(17):1695-1696
pubmed: 32966712
J Infect Dis. 2020 Jun 16;222(1):38-43
pubmed: 32348485
Chest. 2020 Jul;158(1):e9-e13
pubmed: 32243945
Glob Health Med. 2020 Apr 30;2(2):96-101
pubmed: 33330784
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
J Med Virol. 2020 Oct;92(10):1890-1901
pubmed: 32293713
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
Clin Infect Dis. 2020 Nov 5;71(8):1930-1934
pubmed: 32306047
Lancet Infect Dis. 2020 May;20(5):565-574
pubmed: 32213337
Transfusion. 2020 Jun;60(6):1123-1127
pubmed: 32374891
Emerg Infect Dis. 2020 Jul;26(7):1478-1488
pubmed: 32267220